SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Bicycle Therapeutics Reports Third-Quarter 2026 Results and FDA Orphan Drug Designation

Bicycle Therapeutics said nuzefatide pevedotin received FDA Orphan Drug Designation for pancreatic cancer. The headline also reports third-quarter 2026 financial results, but the supplied body is truncated and provides no figures.

BCYC
SquawkNews Desk

Related stories

Restaurant Brands International Reports Third-Quarter Profit M impact | EQUITY | Oct 29, 2026, 03:57 PM UTC Blackstone Mortgage Trust Reports Quarterly Results Blackstone Mortgage Trust reported results for the quarter ended September 30. The supplied summary contains no figures. M impact | EQUITY | Oct 29, 2026, 03:44 PM UTC Alphabet Falls 10% Premarket After Disappointing Results Alphabet shares fell 10% in premarket trading after disappointing results, weighing on AI stocks, the headline says. M impact | EQUITY | Oct 29, 2026, 03:43 PM UTC WPP Reports 2% Third-Quarter Net Revenue Decline M impact | EQUITY | Oct 29, 2026, 03:43 PM UTC Petrobras Reports Record Third-Quarter Production; Ambev Profit Falls 10% The headline reports record production at Petrobras in the third quarter and a 10% decline in Ambev's profit. M impact | EQUITY | Oct 29, 2026, 03:43 PM UTC Renault Reports Higher Third-Quarter Revenue M impact | EQUITY | Oct 29, 2026, 03:42 PM UTC